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Events at 1 Year
BES EES
P-value(n¼3412) (n¼2530)
All-cause death 2.0% (68) 2.0% (50) 1.0
Cardiac death 1.1% (39) 1.0% (26) 0.71
Myocardial infarction 3.1% (104) 2.9% (73) 0.76
Target lesion revascularization (All) 3.4% (115) 3.5% (88) 0.83
Target lesion revascularization (CD) 2.5% (84) 2.5% (63) 1.0
Target vessel revascularization (All) 5.0% (172) 5.0% (127) 1.0
Target vessel revascularization (CD) 3.6% (122) 3.8% (97) 0.63
Stent thrombosis (deﬁnite) 0.5% (17) 0.2% (5) 0.08
Stent thrombosis (deﬁnite / probable) 0.5% (18) 0.4% (10) 0.57
Target vessel failure 6.4% (219) 6.7% (169) 0.71
Diabetic Patients Non-Diabetic Patients
Events at 5 years
EES
(n¼153)
PES
(n¼172)
p-
value
EES
(n¼744)
PES
(n¼730)
p-
value
Death 15.7% (24) 14.5% (25) 0.77 7.7% (57) 9.3% (68) 0.25
Myocardial Infarction 9.2% (14) 13.4% (23) 0.23 6.6% (49) 11.1% (81) <0.01
Target Vessel
Revascularization
9.2% (14) 15.7% (27) 0.08 7.0% (52) 10.4% (76) 0.02
Target Lesion
Revascularization
7.2% (11) 11.0% (19) 0.23 6.0% (45) 9.2% (67) 0.02
Def./Prob. Stent
Thrombosis
5.9% (9) 7.6% (13) 0.55 2.6% (19) 5.5% (40) <0.01
MACE (Primary
Endpoint)
24.8% (38) 34.3% (59) 0.06 17.1% (127) 23.0% (168) <0.01
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: At 5-years EES was superior with regards to efﬁcacy and safety to
PES in non-diabetic patients. In diabetic patients a late trend towards reduction of
MACE was observed with EES compared to PES, mainly driven by a lower rate
of TVR.
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Background: We sought to investigate the long-term outcomes of an abluminal
groove-ﬁlled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort
Medical, Shanghai, China) compared to an everolimus-eluting stent (EES) XIENCE V
in the randomized TARGET I trial.
Methods: A total of 458 patients with single de novo native coronary lesions < ¼24
mm in length and a coronary artery >¼2.25 to < ¼4.0 mm in diameter were enrolled
in the TARGET I study, a prospective, randomized, non-inferiority trial. The primary
endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The secondary
endpoint, target lesion failure (TLF), was deﬁned as the composite of cardiac death,
target vessel myocardial infarction (TV-MI), and ischemia-driven target lesion
revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6- and 12-month,
and annually up to 5 years for all enrolled patients. All adverse clinical events were
adjudicated by an independent committee.
Results: Previously reported results demonstrated FIREHAWK stent was non-inferior
to XIENCE V EES for the primary endpoint of 9-month in-stent LLL (0.130.24 mm
vs. 0.130.18 mm, p¼0.94; difference and 95% conﬁdence interval 0.00 [-0.04,
0.04] mm; p for non-inferiority < 0.0001), and had a comparable clinical outcome at
2 years. There were still no signiﬁcant differences between the two groups up to 3
years, and no deﬁnite/probable stent thrombosis occurred in FIREHAWK group.
(Table)Table. Clinical Outcomes through 3 Years
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Clinical Follow-Up, % (n/N) 99.6
(226/
227)
100
(231/
231)
0.50 99.6
(226/
227)
100
(231/
231)
0.50 97.4
(221/
227)
98.7
(228/
231)
0.34
Death, % (n) 0.4 (1) 0.9 (2) 1.00 0.4 (1) 0.9 (2) 1.00 1.8 (4) 1.8 (4) 1.00
Cardiac Death 0.4 (1) 0 (0) 1.00 0.4 (1) 0 (0) 1.00 0.9 (2) 0.4 (1) 0.62
Myocardial Infarction, % (n) 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50 1.4 (3) 3.1 (7) 0.34
Q Wave MI 0 (0) 0 (0) - 0 (0) 0 (0) - 0.0 (0) 0.4 (1) 1.00
Non Q Wave MI 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50 1.4 (3) 2.6 (6) 0.50
TV-MI 1.3 (3) 1.7 (4) 1.00 1.3 (3) 1.7 (4) 1.00 1.4 (3) 2.2 (5) 0.72
iTLR, % (n) 0.4 (1) 0.4 (1) 1.00 0.9 (2) 0.9 (2) 1.00 1.8 (4) 1.3 (3) 0.75
Any Revascularization, % (n) 1.8 (4) 4.8 (11) 0.07 2.2 (5) 6.1 (14) 0.04 4.5 (10) 7.5 (17) 0.19
TLF, % (n) 2.2 (5) 2.2 (5) 1.00 2.7 (6) 2.6 (6) 0.97 4.1 (9) 3.5 (8) 0.75
PoCE (composite of all cause death,
all MI, and any revascularization), % (n)
3.5 (8) 7.4 (17) 0.07 4.0 (9) 8.7 (20) 0.04 7.2 (16) 11.0 (25) 0.17
Deﬁnite/Probable Stent Thrombosis, %
(n)
0 (0) 0 (0) - 0 (0) 0 (0) - 0.0 (0) 0.4 (1) 1.00
B172 JACC Vol 64/11/Suppl B j SeptemberConclusions: In the multicenter randomized TARGET I trial, the 3-year follow-up
results conﬁrmed that the novel FIREHAWK stent had a durable safety and efﬁcacy
proﬁle, which was comparable to the XIENCE V EES for the treatment of single de
novo native coronary lesions. (ClinicalTrials.gov Identiﬁer: NCT01196819)
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Background: Drug-eluting stents with biodegradable polymers have been developed
to reduce the risk of very late adverse events. Distinct studies have indicated non-
inferiority of the biodegradable polymer-coated biolimus-eluting stent (Nobori;
BES) compared to the durable polymer-coated everolimus-eluting stent (Xience or
Promus; EES) with regards to safety and efﬁcacy at 1 year. However, these trials
were not powered to detect differences in low-frequency events.
Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned
5942 patients to BES or EES and is at present the largest pooled analysis of BES in
all-comers requiring percutaneous coronary intervention (PCI). The pre-speciﬁed
composite endpoint was target vessel failure (TVF) deﬁned as cardiac death, target
vessel related myocardial infarction (MI), or clinical-indicated target vessel revascu-
larization (TVR-CD).
Results: The pooled unadjusted 1-year clinical outcomes of the 5942 study patients
(8094 lesions) are tabulated. Covariate adjusted analyses accounting for baseline im-
balances between trials conﬁrmed non-signiﬁcant differences between stent type and
clinical outcomes. The trend for a higher deﬁnite stent thrombosis rate in the BES group
was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60]; p¼0.16).Conclusions: At 1-year the biodegradable polymer-coated BES has similar safety and
efﬁcacy outcomes as the durable polymer-coated EES. Longer follow-up data is
needed to determine the role of biodegradable polymer-coated BES in real world
clinical practice.
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Background: These are the ﬁrst long-term randomized adjudicated trial data of ﬁve
year results of the Genous bio-engineered endothelial progenitor cell capturing stent
(OrbusNeich BV, Fort Lauderdale, FL, USA) compared with a paclitaxel-eluting
stent(PES).
Methods: In this prospective randomized trial, patients with de-novo coronary artery
lesions carrying a high risk of restenosis (chronic total occlusion,lesion length >
23mm,vessel diameter < 2.8mm or any lesion in a diabetic patient) were randomized
1:1 to the Genous or a PES. The current primary endpoint is adjudicated target vessel
failure (TVF) at 5-years, a composite of cardiac death, myocardial infarction (MI) and
target vessel revascularization. Clinical event rates were estimated by Kaplan-Meier
method and compared with a log-rank test.
Results: A total of 193 patients were included with complete follow-up in 97% of the
subjects. The primary endpoint of TVF was similar at 5 years with Genous 23.8% vs13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Randomized Trials
